Table 1.
Laboratory studies during the patient’s current admission compared with the initial encounter 2 years prior
| Laboratory study | Admission 1 (2 years prior) |
Admission 2 | Reference range |
| Sodium (mmol/L) | 139 | 128 | 135–145 |
| Potassium (mmol/L) | 4.0 | 2.9 | 3.6–5.0 |
| Chloride (mmol/L) | 101 | 89 | 98–109 |
| Bicarbonate (mmol/L) | 26 | 20 | 22–31 |
| Blood urea nitrogen (mg/dL) | 4 | 79 | 6–23 |
| Creatinine (mg/dL) | 0.55 | 7.31 | 0.67–1.17 |
| Albumin (g/dL) | 3.0 | 2.4 | 3.5–5.2 |
| Aspartate aminotransferase (U/L) | 199 | 113 | 10–50 |
| Alanine aminotransferase (U/L) | 96 | 51 | 10–50 |
| Alkaline phosphatase (U/L) | 132 | 153 | 40–129 |
| Bilirubin, total (mg/dL) | 10.1 | 38.5 | 0.2–1.3 |
| Bilirubin, conjugated (mg/dL) | 4.9 | >20 | 0.0–0.3 |
| International normalised ratio | 1.4 | 3.6 | 0.9–1.1 |
| White blood cell count | 7×109/ L | 21.24×109/ L | 4.22–10.33×109/ L |
| Haemoglobin (g/L) | 137 | 98 | 132–169 |
| Mean corpuscular volume (fL) | 103.2 | 92.9 | 79.0–92.2 |
| Platelet count | 242×109/ L | 245×109/ L | 160–383×109/ L |
| Ferritin (ng/mL) | 869 | 750 | 30–400 |
| Gamma glutamyl transferase (U/L) | Not performed | 105 | 8–61 |
| IgA (mg/dL) | Not performed | 464 | 70–400 |
| Ceruloplasmin (mg/dL) | 26 | 17.6 | 19–31 |
| Copper, serum (μg/dL) | 132 | 62 | 63.7–140.12 |
| Copper, urine 24 hours (μg/24 hours) | Not performed | 67 | 3–50 |
| Hepatitis A virus antibody IgG | Reactive | Reactive | Non-reactive |
| Hepatitis B surface antigen | Non-reactive | Non-reactive | Non-reactive |
| Hepatitis B core antibody | Non-reactive | Non-reactive | Non-reactive |
| Hepatitis B surface antibody | Reactive | Reactive | Non-reactive |
| Hepatitis C antibody | Non-reactive | Non-reactive | Non-reactive |
| Peritoneal fluid, nucleated cells/μL | 74 | 69 | ≤499/μL |
| Peritoneal fluid, albumin (g/dL) | 0.4 | 0.3 | N/a |
| Peritoneal fluid, protein (g/dL) | 0.8 | 0.4 | N/a |
| Peritoneal lactate dehydrogenase (U/L) | 49 | Not performed | N/a |
N/a, not applicable.